Gout combined with metabolic fatty liver disease
Conditions
Interventions
treatment group:Eliminating turbidity and dredging channels method granules, one pack per time, BID+ febuxostat tablets, oral, 20-40mg per dose, qd +healthy lifestyle management.
Control group:Simulant of Eliminating turbidity and dredging channels method granules, one pack per time, BID+ febuxostat tablets, oral, 20-40mg per dose, qd +healthy lifestyle management.
Sponsors
The First Teaching Hospital of Tianjin University of TCM
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria of Western medicine and traditional Chinese medicine syndromes for this disease can be included in treatment; 2. The patient did not receive any other medication or treatment measures within two weeks prior to entering the clinical trial; 3. Patients who have not received standardized treatments such as strict lifestyle interventions in the past; 4.Aged 18 to 70 years 5. Patients who voluntarily participate and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who do not meet the inclusion criteria; 2. Patients with specific liver diseases such as alcoholic liver disease (ALD), viral hepatitis, autoimmune liver disease, hepatolenticular degeneration, etc., can lead to fatty liver; 3. Medications (such as tamoxifen, amiodarone, sodium valproate, methotrexate, glucocorticoids, etc.), total parenteral nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome, etc ß Fatty liver caused by lipoprotein deficiency and some syndromes related to insulin resistance (lipoatrophic diabetes, Mauriac syndrome); 4. Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, and hematopoietic systems, malignant tumors, other serious comorbidities, or mental illness; 5. The patient has diabetes or is receiving anti diabetes drugs; 6. Patients who are using NAFLD treatment drugs (including Chinese herbal decoction, traditional Chinese patent medicines and simple preparations and chemical drugs) and ALT = 5 times the standard value; 7. Known allergies to the components of the research product or patients with allergic constitution; 8. Pregnant and lactating women, as well as women who refuse to maintain the contraceptive measures recognized by the researchers throughout the entire study process and are at risk of pregnancy; 9. Those who have participated in other clinical trials in the past three months or are currently participating in other clinical trials; 10. Those who are unable to follow medical advice for therapeutic lifestyle changes; 11. Suspect having a history of drug abuse or having other patients who do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Controlled attenuation parameter (CAP) value of liver fat;Uric acid decrease before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine syndrome score;Patient satisfaction score;Acute attacks of gout during treatment;Laboratory indicators;Changes in liver ultrasound imaging before and after treatment; | — |
Countries
China
Contacts
Public ContactLiu Wei
First Teaching Hospital of Tianjin University of TCM
Outcome results
None listed